Lithium

Lithium has been studied in 108 papers since 2016: 4 trials and 44 observational studies in people, 14 in animals, 3 in cells, 42 reviews; 47 in the past year. It is an approved medicine. The newest story, Oct 7, 2026: “Starting lithium linked to lower death and dementia risks”.

InterventionApproved 1970

108 papers study it61 more mention it139 findingsUpdated

PubChemMeSH

Research on it is growing 9% faster than aging research as a whole: 12 papers in the latest year counted

11 new papers in 30 daysSee all 167 papers on lithium

At a glance

Independent labs report longer fly lifespan with lithium and lower dementia risk associated with its use in people with bipolar disorder; a mouse study shows no clear lifespan effect. Human trials report cognitive benefits in amnestic mild cognitive impairment, while an observational study links longer treatment with advanced kidney disease. Some papers declare company ties.

139 findings in 64 papers from 2016 to 2026, 17 of them since April 2026

Independent labs found the same change in worms or flies and people. 38 independent labs in 17 countries; 119 trials, 2 about aging, 55 with no results posted.

“Participants in the placebo group displayed cognitive and functional decline, whereas lithium-treated patients remained stable over 2 years.”
Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trialThe British journal of psychiatry : the journal of mental science2019doi:10.1192/bjp.2019.76

8 of its findings point the other way.

Worms or flies and humans: replicated by independent labs. Cells and mice: a single group.
  • 38 independent labs in 17 countries
  • 8 findings against
  • 119 trials, 2 about aging, 55 with no results posted
  • Funders: São Paulo Research Foundation and others
  • 7 of 104 findings with company ties
  • Human trial4
  • Humans42
  • Animals11
  • Model organisms3
  • Cells3

Studies in people

2 studies gave lithium to people and measured what changed.

What changedDesignPeopleSource

up: Improves cognitive function25.5 vs 18.3

up: Improves verbal fluency34.4 vs 11.6

no change: Has no effect on depressive symptoms

Randomized trialmean 13.6 years (SD, 1.1; min: 11.0, max: 15.0 years)36 peopleFormer participants of the Lithium-MCI trial with amnestic mild cognitive impairment at baselineRevista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), Sep 2, 2022

down: Prevents cognitive and functional decline

up: Improves memory and attention performance

up: Increases amyloid-beta 1-42

Randomized trial2 years61 peopleolder adultsOlder adults; amnestic mild cognitive impairmentThe British journal of psychiatry : the journal of mental science, Apr 6, 2019

What did studies of lithium find?

63

Studies of lithium measured 63 outcomes; the most studied are telomere length (6 studies), cognitive function (5) and mortality (4).

Telomere length

no changein humans3upin humans2upin human cells1

6 studies
  1. Lithium was not clearly linked with telomere length in humans (prescribed lithium) (β = - 0.022, 95% CI - 0.081 to 0.037, p = 0.47).

    “There was no evidence that the number of prescriptions (β = - 0.022, 95% CI - 0.081 to 0.037, p = 0.47)”

    Humansprescribed lithiumn = 591

    The duration of lithium use and biological ageing: telomere length, frailty, metabolomic age and all-cause mortality

    GeroScience

  2. Lithium was not clearly linked with telomere length in humans (bipolar disorder).

    “In bipolar patients, there was no correlation between TL and duration of treatment.”

    Humansbipolar disordermean 16.5 years

    Decreased leucocyte telomere length in male patients with chronic bipolar disorder: lack of effect of long-term lithium treatment

    Acta neuropsychiatrica

  3. Lithium was not clearly linked with telomere length in humans.

    “we did not find any significant effect of lithium treatment on TL.”

    Humans

    Expression of telomerase reverse transcriptase positively correlates with duration of lithium treatment in bipolar disorder

    Psychiatry research

  4. Lithium is linked with higher telomere length in humans (chronic use in bipolar disorder patients) (p = 0.03).

    “chronic use in a sample of 384 bipolar disorder patients is associated with longer telomeres (p = 0.03)”

    Humanschronic use in bipolar disorder patientschronic usen = 384

    The polygenic nature of telomere length and the anti-ageing properties of lithium

    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

  5. Lithium increases telomere length in humans (chronic treatment).

    “chronic lithium treatment is associated with modulatory effects on aging biomarkers, particularly increased telomere length and telomerase activity”

    Reviewchronic treatment

    Exploring accelerated aging as a target of bipolar disorder treatment: A systematic review

    Journal of psychiatric research

  6. Lithium increases telomere length in LCLs from patients with bipolar disorder.

    “lithium treatment significantly increased telomere length in LCLs from patients, but not in controls”

    Cellsin LCLs from patients with bipolar disorderlymphoblastoid cell linen = 14

    The anti-aging effects of lithium in lymphoblastoid cell lines from patients with bipolar disorder and controls

    Journal of psychiatric research

More on Telomere length

Cognitive function

upin reviews2upin animals1upin humans1downin mice1

5 studies
  1. Lithium improves cognitive function in humans (25.5 vs 18.3).

    “We found statistically significant differences in current mean Mini Mental State Examination scores according to previous treatment groups, with higher scores obtained the lithium group than the control group (25.5 [SD, 5.3] vs. 18.3 [SD, 10.9], p = 0.04).”

    Human trialmean 13.6 years (SD, 1.1; min: 11.0, max: 15.0 years)n = 36

    Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment

    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

  2. Lithium improves cognitive function in humans (amnestic mild cognitive impairment) (25.5 [SD, 5.3] vs. 18.3 [SD, 10.9], p = 0.04, Cohen's d = 0.92).

    “We found statistically significant differences in current mean Mini Mental State Examination score according to previous treatment group (25.5 [SD, 5.3] vs. 18.3 [SD, 10.9], p = 0.04).”

    Human trialamnestic mild cognitive impairmentafter 11 to 15 yearsn = 36

    Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment

    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

  3. Lithium protects against cognitive function in mice (Alzheimer's disease mouse models with reduced dietary lithium).

    “Remarkably, lithium supplementation prevented these changes and preserved neuronal and cognitive function.”

    ReviewAlzheimer's disease mouse models with reduced dietary lithiumsupplementation

    The interplay of homeostasis, inflammation, and oxidative stress in neurodegenerative disorders: the role of biological markers, antioxidants, lithium, and TMS - a proposed framework for preventing neurodegenerative disorders through biomarkers and multimodal therapies

    Frontiers in aging neuroscience

  4. Lithium improves cognitive function in animal models of Alzheimer's disease.

    “significantly improved cognitive behavior in animal models of AD”

    Reviewin animal models of Alzheimer's disease

    Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease

    Ageing research reviews

  5. Lithium improves cognitive function (aging).

    “low-dose lithium (≤0.5 mM) may be beneficial for cardiovascular, musculoskeletal, metabolic, and cognitive function”

    Reviewaging≤0.5 mM

    Beyond its Psychiatric Use: The Benefits of Low-dose Lithium Supplementation

    Current neuropharmacology

  6. Lithium improves cognitive function in animals (Alzheimer's disease models) (Significant benefit in nine of ten animal studies).

    “Nine of ten animal studies of lithium showed a statistically significant benefit in Alzheimer's models.”

    ReviewAlzheimer's disease models

    Repurposing Proteostasis-Modifying Drugs to Prevent or Treat Age-Related Dementia: A Systematic Review

    Frontiers in physiology

Mortality

no changein humans3downin humans1HR 0.56

4 studies
  1. Lithium is linked with lower mortality in humans (vs valproate) (HR 0.56, 95% CI 0.39-0.80).

    “Mortality was lower with lithium (HR, 0.56; 95% CI, 0.39-0.80)”

    Humansvs valproatelithium carbonateserum measurements ≤0.40 mmol/L730 days

    Low-dose lithium vs valproate and incident dementia diagnoses in older adults: A propensity-matched cohort study using electronic health record data

    Psychiatry research

  2. Lithium was not clearly linked with mortality in adults with bipolar disorder compared with valproate.

    “No significant between-group differences were observed for vascular dementia, mortality, or ESRD.”

    Humansin adults with bipolar disorder compared with valproate

    Lithium versus valproate in bipolar disorder: Associations with dementia, mortality, suicide attempt, and end-stage renal disease in adults aged 45 years and older - a propensity score-matched retrospective cohort study

    Psychiatry research

  3. Lithium was not clearly linked with mortality in humans (prescribed lithium).

    “The duration of lithium use did not predict all-cause mortality.”

    Humansprescribed lithiumn = 591

    The duration of lithium use and biological ageing: telomere length, frailty, metabolomic age and all-cause mortality

    GeroScience

  4. Lithium was not clearly linked with mortality in humans (older adults with psychiatric disorders) (AOR=1.12; 95%CI=0.45-2.79; p=0.810).

    “There was no significant association between lithium use and all-cause mortality [AOR=1.12; 95%CI=0.45-2.79; p=0.810]”

    Humansolder adults with psychiatric disorders5-yearn = 561

    Impact of lithium on mortality among older adults with major psychiatric disorders: A 5-year prospective multicenter study

    Aging & mental health

Lifespan

upin flies1no changein mice1upin worms1

3 studies
  1. Lithium showed no clear effect on lifespan in mice within the tolerable dosing range.

    “Within the tolerable dosing range, we saw some mildly positive effects of lithium on health span but not on lifespan.”

    Animalswithin the tolerable dosing range

    Lithium can mildly increase health during ageing but not lifespan in mice

    Aging cell

  2. Lithium extends lifespan in non-transgenic GRU101 and GRU102 worms.

    “Individually, metformin and lithium extended the lifespan of both non-transgenic GRU101 controls and GRU102.”

    Model organismsin non-transgenic GRU101 and GRU102 worms

    Drug synergy as a strategy for compression of morbidity in a Caenorhabditis elegans model of Alzheimer's disease

    GeroScience

  3. Lithium extends lifespan in flies.

    “lithium extends lifespan in female and male Drosophila, when administered throughout adulthood or only later in life.”

    Model organismsThroughout adulthood or only later in lifeFemale and males

    Lithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis

    Cell reports

Cellular senescence

downin humans1downin mice1downin reviews1

2 studies
  1. Lithium is linked with lower cellular senescence in psychiatric patients on lithium carbonate therapy.

    “lithium carbonate therapy inhibited GSK3β activity and mitigated senescence signaling in urinary exfoliated podocytes and was associated with preservation of kidney function.”

    Humansin psychiatric patients on lithium carbonate therapyurinary exfoliated podocytes

    Age-related GSK3β overexpression drives podocyte senescence and glomerular aging

    The Journal of clinical investigation

  2. Lithium decreases cellular senescence in experimental studies under oxidative, inflammatory, and genotoxic stress.

    “Experimental studies indicate that lithium attenuates several hallmarks of cellular senescence and promotes cellular resilience under conditions of oxidative, inflammatory, and genotoxic stress.”

    Reviewin experimental studies under oxidative, inflammatory, and genotoxic stress

    Lithium as a Potential Senostatic Agent in Central Nervous System Aging and Bipolar Disorder

    Pharmaceuticals (Basel, Switzerland)

  3. Lithium decreases cellular senescence in mice (started later in life).

    “therapeutic targeting of GSK3β by microdose lithium later in life reduced senescence signaling and delayed kidney aging in mice.”

    Animalsstarted later in lifemicrodose

    Age-related GSK3β overexpression drives podocyte senescence and glomerular aging

    The Journal of clinical investigation

More on Cellular senescence

Bipolar disorder

downin humans2

2 studies
  1. Lithium decreases bipolar disorder in humans (maintenance treatment).

    “Lithium is effective both in treating acute mania, as an adjunctive antidepressant, and as a maintenance treatment in bipolar disorder.”

    Reviewmaintenance treatment

    Lithium: current state of the art and future directions

    International journal of bipolar disorders

  2. Lithium decreases bipolar disorder in bipolar disorders.

    “was subsequently effective at relatively high doses to "normalize" a subset of patients with bipolar disorders.”

    Reviewin bipolar disordersrelatively high doses

    Lithium Ions as Modulators of Complex Biological Processes: The Conundrum of Multiple Targets, Responsiveness and Non-Responsiveness, and the Potential to Prevent or Correct Dysregulation of Systems during Aging and in Disease

    Biomolecules

More on Bipolar disorder

GSK3B

downin mice1downin reviews1

2 studies
  1. Lithium inhibits GSK3B.

    “lithium modulates aging by inhibiting glycogen synthase kinase-3β (GSK-3β), and the phosphatidylinositol (PI) cycle”

    Reviewneuron

    Intracellular effects of lithium in aging neurons

    Ageing research reviews

  2. Lithium inhibits GSK3B in accelerated aging.

    “In addition, this microdose of lithium inhibited the activation of glycogen synthase kinase-3beta (GSK-3β)”

    Animalsin accelerated agingmicrodosefemales

    Microdose lithium improves behavioral deficits and modulates molecular mechanisms of memory formation in female SAMP-8, a mouse model of accelerated aging

    PloS one

More on GSK3B

Epigenetic age

no changein human cells1no changein humans1

2 studies
  1. Lithium was not clearly linked with epigenetic age in BD patients categorized as excellent responders vs non-responders.

    “No significant differences in age acceleration were found between Ex-Rp and N-Rp for any of the epigenetic clocks analysed.”

    Humansin BD patients categorized as excellent responders vs non-respondersperipheral blood

    Lithium response in bipolar disorder: Epigenome-wide DNA methylation signatures and epigenetic aging

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

  2. Lithium showed no clear effect on epigenetic age in LCLs from patients and controls.

    “lithium did not induce any changes in epigenetic age in cells from either patients or controls”

    Cellsin LCLs from patients and controlslymphoblastoid cell line

    The anti-aging effects of lithium in lymphoblastoid cell lines from patients with bipolar disorder and controls

    Journal of psychiatric research

More on Epigenetic age

Inflammation

downin reviews2

2 studies
  1. Lithium decreases inflammation (aging).

    “potential benefits on the aging process and age-related diseases of these systems, such as cardiovascular disease, osteoporosis, sarcopenia, obesity and type 2 diabetes, Alzheimer's disease, and the chronic low-grade inflammatory state known as inflammaging.”

    Reviewaging≤0.5 mM

    Beyond its Psychiatric Use: The Benefits of Low-dose Lithium Supplementation

    Current neuropharmacology

  2. Lithium decreases inflammation.

    “This action of Lithium can effectively counteract neuroinflammation and neurodegeneration.”

    Review

    The Actions of Lithium on Glaucoma and Other Senile Neurodegenerative Diseases Through GSK-3 Inhibition: A Narrative Review

    Cureus

More on Inflammation

Cardiomyocyte DNA synthesis

upin mice1

1 study
  1. Lithium increases cardiomyocyte DNA synthesis in mice (maternal lithium treatment during pregnancy).

    “In vivo, treatment of pregnant mice with lithium increased DNA synthesis in the CMs of their embryos.”

    Animalsmaternal lithium treatment during pregnancycardiomyocyte

    Network-enabled drug repurposing identifies lithium to promote cardiomyocyte proliferation

    bioRxivPreprint

Functional state

no changein humans1

1 study
  1. Lithium showed no clear effect on functional state in humans.

    “In contrast, no significant differences were found between the groups regarding depressive symptoms (Montgomery-Åsberg Depression Rating Scale), functional state (IQCODE, CDR-Global Score, CDR-Sum of Boxes, and FAST), or estimated time to decline in instrumental or basic activities of daily living.”

    Human trialmean 13.6 years (SD, 1.1; min: 11.0, max: 15.0 years)n = 36

    Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment

    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

Depressive symptoms

no changein humans1

1 study
  1. Lithium showed no clear effect on depressive symptoms in humans.

    “In contrast, no significant differences were found between the groups regarding depressive symptoms (Montgomery-Åsberg Depression Rating Scale), functional state (IQCODE, CDR-Global Score, CDR-Sum of Boxes, and FAST), or estimated time to decline in instrumental or basic activities of daily living.”

    Human trialmean 13.6 years (SD, 1.1; min: 11.0, max: 15.0 years)n = 36

    Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment

    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

Verbal fluency

upin humans1

1 study
  1. Lithium improves verbal fluency in humans (34.4 vs 11.6).

    “The lithium group also had better performance in the phonemic Verbal Fluency Test than the control group (34.4 [SD, 14.4] vs. 11.6 [SD, 10.10], p < 0.001).”

    Human trialmean 13.6 years (SD, 1.1; min: 11.0, max: 15.0 years)n = 36

    Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment

    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

Amyloid-beta 1-42

upin humans1

1 study
  1. Lithium increases amyloid-beta 1-42 in humans (amnestic mild cognitive impairment).

    “with a significant increase in CSF amyloid-beta peptide (Aβ1-42) after 36 months”

    Human trialamnestic mild cognitive impairmentcerebrospinal fluid36 months

    Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

    The British journal of psychiatry : the journal of mental science

More on Amyloid-beta 1-42

Memory and attention performance

upin humans1

1 study
  1. Lithium improves memory and attention performance in humans (amnestic mild cognitive impairment).

    “Lithium treatment was associated with better performance on memory and attention tests after 24 months”

    Human trialamnestic mild cognitive impairment24 months

    Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

    The British journal of psychiatry : the journal of mental science

All 63

What is lithium linked with?

42

Studies link lithium with 42 measures, most often dementia (10 studies), chronic kidney disease (2) and Alzheimer's disease (2).

Dementia

downin humans10HR 0.38–0.689

10 studies
  1. Lithium is associated with dementia in humans (HR 0.68, 95% CI 0.60–0.76).

    “Lithium initiation was also associated with a lower recorded risk of incident dementia (HR 0.68, 95% CI 0.60-0.76; p < 0.001).”

    HumansIncident dementia following lithium initiation compared with valproate initiation; propensity score-matched groupsn = 22,098

    Starting lithium linked to lower death and dementia risks

    Frontiers in neurology

  2. Lithium is linked with a lower risk of dementia in humans (vs valproate) (HR 0.38, 95% CI 0.24-0.60).

    “All-cause dementia occurred in 25/795 (3.1%) lithium versus 69/832 (8.3%) valproate users (HR, 0.38; 95% CI, 0.24-0.60; P < .001).”

    Humansvs valproatelithium carbonateserum measurements ≤0.40 mmol/L730 days

    Low-dose lithium vs valproate and incident dementia diagnoses in older adults: A propensity-matched cohort study using electronic health record data

    Psychiatry research

  3. Lithium is linked with a lower risk of dementia in adults with bipolar disorder compared with valproate (HR 0.689, 95% CI 0.578-0.822; RR 0.658, 95% CI 0.556-0.778).

    “Lithium use was associated with a lower risk of all-cause dementia than valproate use (207 [7.1%] vs 311 [10.8%]; Relative risk [RR], 0.658; 95% confidence interval [CI], 0.556-0.778; Hazard ratio [HR], 0.689; 95% CI, 0.578-0.822; both P<.001).”

    Humansin adults with bipolar disorder compared with valproate

    Lithium versus valproate in bipolar disorder: Associations with dementia, mortality, suicide attempt, and end-stage renal disease in adults aged 45 years and older - a propensity score-matched retrospective cohort study

    Psychiatry research

  4. Lithium is linked with a lower risk of dementia in humans (PR = 0.965, 95% CI: 0.950, 0.981).

    “those with high concentrations had lower dementia prevalence (prevalence ratio [PR] = 0.965, 95% CI: 0.950, 0.981)”

    Humans

    Associations between low-dose drinking water lithium exposure and Dementia: A nationwide U.S. ecological study

    Environmental pollution (Barking, Essex : 1987)

  5. Lithium is associated with dementia in humans (bipolar disorder).

    “Lithium carries the most consistent observational signal for reduced dementia risk, with plausible antioxidant and neurotrophic mechanisms”

    Reviewbipolar disorder

    Oxidative Stress, Brain Antioxidant Imaging, and Cognitive Aging in Older Adults With Bipolar Disorder

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

  6. Lithium lowers the risk of dementia in humans (HR 0.633, 95% CI: 0.517-0.775).

    “Four cohort studies showed a pooled hazard ratio (HR) of 0.633 (95% CI: 0.517-0.775; p = 0.003), indicating ∼37% lower dementia risk with lithium.”

    Review

    Lithium exposure and risk of dementia and Alzheimer's disease: A systematic review and meta-analysis

    Journal of Alzheimer's disease : JAD

  7. Lithium lowers the risk of dementia in humans (observational cohorts).

    “Observational cohorts also associate lithium exposure with lower dementia incidence”

    Reviewobservational cohorts

    LITHIUM AND ALZHEIMER’S DISEASE: POTENTIAL NEUROPROTECTIVE EFFECTS AND THERAPEUTIC PERSPECTIVES

    International Journal of Innovative Technologies in Social Science

  8. Lithium lowers the risk of dementia in humans (cumulative exposure in epidemiological studies).

    “epidemiological studies have associated cumulative lithium exposure with reduced dementia risk”

    Reviewcumulative exposure in epidemiological studies

    The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia: A Narrative Review

    JAMA psychiatry

  9. Lithium lowers the risk of dementia in humans (long-term lithium users).

    “Large observational studies report lower dementia incidence and reduced fracture risk in long-term lithium users, together with increases in bone mineral density.”

    Reviewlong-term lithium users

    Lithium and the Brain-Bone Axis: A Bridge between Osteoporosis and Alzheimer's Disease

    Current osteoporosis reports

  10. Lithium is associated with dementia in humans.

    “Higher (but still trace) lithium levels in drinking water are associated with lower rates of dementia.”

    Reviewin drinking watertrace levels

    Lithium: current state of the art and future directions

    International journal of bipolar disorders

More on Dementia

Chronic kidney disease

upin humans2HR 1.62

2 studies
  1. Lithium is associated with chronic kidney disease in humans (occupational multi-metal exposure).

    “Li, Al, Cr, and Ni showed positive associations with CKD, whereas Zn and Se showed inverse associations.”

    Humansoccupational multi-metal exposure

    Associations of Mixed-Metal Exposure with Incident Chronic Kidney Disease in an Occupational Population: A Nested Case–Control Study

    Toxics

  2. Lithium is associated with chronic kidney disease in humans (Bipolar disorder; compared with nonlithium exposure) (HR 1.62, 95% CI 1.25–2.11).

    “Across 6 cohorts, lithium was associated with a higher risk of CKD than nonlithium exposure”

    ReviewBipolar disorder; compared with nonlithium exposure

    Long term lithium exposure and chronic kidney disease in the elderly with bipolar disorder: a systematic review and meta-analysis

    Current opinion in psychiatry

More on Chronic kidney disease

Alzheimer's disease

downin humans2HR 0.656

2 studies
  1. Lithium is linked with a lower risk of Alzheimer's disease in humans (bipolar disorder or recurrent major depressive disorder) (hazard ratio = 0.48; 95% CI = 0.32-0.73; log rank p < 0.001).

    “Time-to-event analysis demonstrated a lower hazard of AD diagnosis among lithium-exposed patients (hazard ratio = 0.48; 95% CI = 0.32-0.73; log rank p < 0.001).”

    Humansbipolar disorder or recurrent major depressive disorderat least one year

    Association of Lithium Exposure With Alzheimer's Disease: A Propensity Score-Matched Cohort Study

    Cureus

  2. Lithium lowers the risk of Alzheimer's disease in humans (HR 0.656, 95% CI: 0.427-1.009).

    “Two individual-level studies showed HR 0.656 (95% CI: 0.427-1.009; p = 0.052) for AD diagnosis.”

    Review

    Lithium exposure and risk of dementia and Alzheimer's disease: A systematic review and meta-analysis

    Journal of Alzheimer's disease : JAD

More on Alzheimer's disease

Mortality

downin humans1upin humans1HR 0.58

2 studies
  1. Lithium is associated with mortality in humans (Lithium initiation compared with valproate initiation; propensity score-matched groups) (HR 0.58, 95% CI 0.53–0.63).

    “Lithium initiation was associated with a lower recorded risk of all-cause mortality than valproate initiation”

    HumansLithium initiation compared with valproate initiation; propensity score-matched groupsn = 22,098

    Starting lithium linked to lower death and dementia risks

    Frontiers in neurology

  2. Lithium is linked with a higher risk of mortality in humans among individuals with dementia (MR = 1.017, 95% CI: 1.007, 1.027).

    “all-cause mortality among individuals with dementia was higher in high-lithium counties (mortality rate [MR] = 1.017, 95% CI: 1.007, 1.027)”

    Humansamong individuals with dementia

    Associations between low-dose drinking water lithium exposure and Dementia: A nationwide U.S. ecological study

    Environmental pollution (Barking, Essex : 1987)

Cardiovascular disease

downin humans2HR 0.38

2 studies
  1. Lithium is linked with a lower risk of cardiovascular disease in humans (bipolar disorder).

    “significant age-by-lithium interactions for cardiovascular (χ2 = 9.27, p = 0.002)”

    Humansbipolar disorder

    The Association Between Lithium Use and Physical Comorbidities Across Age Groups: A Cross-Sectional Study From the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE-BD) Project

    Acta psychiatrica Scandinavica

  2. Lithium is linked with a lower risk of cardiovascular disease in patients with bipolar disorder (HR = 0.38; 95% CI 0.18-0.78).

    “Lithium use was associated with a significantly lower risk of overall CVD (HR = 0.38; 95% CI 0.18-0.78)”

    Humansin patients with bipolar disordern = 2,945

    Association of lithium treatment with incident cardiovascular disease in patients with bipolar disorder: A claims-based longitudinal cohort study

    Journal of affective disorders

More on Cardiovascular disease

Cancer

mixedin humans1OR 0.53–1.07

1 study
  1. Lithium is associated with cancer in humans (Residents of rural US counties) (Adjusted ORs 0.53–1.07; less consistent reductions).

    “reduced odds of cancer diagnosis were less consistent (adjusted ORs ranged from 0.53 to 1.07)”

    HumansResidents of rural US countiesGroundwater lithium ≥30 μg/L versus <10 μg/L

    Groundwater Lithium Availability Association with Physical and Mental Health Outcomes in United States Populations

    Research SquarePreprint

More on Cancer

Kidney disease

downin humans1OR 0.49–0.93

1 study
  1. Lithium is associated with kidney disease in humans (Residents of rural US counties) (Adjusted ORs 0.49–0.93).

    “functional impairment (adjusted ORs ranged from 0.33 to 0.87), and kidney disease diagnosis (adjusted ORs ranged from 0.49 to 0.93)”

    HumansResidents of rural US countiesGroundwater lithium ≥30 μg/L versus <10 μg/L

    Groundwater Lithium Availability Association with Physical and Mental Health Outcomes in United States Populations

    Research SquarePreprint

More on Kidney disease

Functional impairment

downin humans1OR 0.33–0.87

1 study
  1. Lithium is associated with functional impairment in humans (Residents of rural US counties) (Adjusted ORs 0.33–0.87).

    “reduced odds of depression diagnosis (adjusted odds ratios [ORs] ranged from 0.64 to 0.88), functional impairment (adjusted ORs ranged from 0.33 to 0.87)”

    HumansResidents of rural US countiesGroundwater lithium ≥30 μg/L versus <10 μg/L

    Groundwater Lithium Availability Association with Physical and Mental Health Outcomes in United States Populations

    Research SquarePreprint

Depression

downin humans1OR 0.64–0.88

1 study
  1. Lithium is associated with depression in humans (Residents of rural US counties) (Adjusted ORs 0.64–0.88).

    “exhibited consistently reduced odds of depression diagnosis (adjusted odds ratios [ORs] ranged from 0.64 to 0.88)”

    HumansResidents of rural US countiesGroundwater lithium ≥30 μg/L versus <10 μg/L

    Groundwater Lithium Availability Association with Physical and Mental Health Outcomes in United States Populations

    Research SquarePreprint

More on Depression

Congenital heart disease

upin humans1

1 study
  1. Lithium is associated with congenital heart disease in utero exposure; relative to other mood stabilizers.

    “in utero exposure to lithium was associated with an increased incidence of congenital heart defects, in males but not females.”

    Humansin utero exposure; relative to other mood stabilizersheartmales

    Network-enabled drug repurposing identifies lithium to promote cardiomyocyte proliferation

    bioRxivPreprint

More on Congenital heart disease

All 42

Has lithium been tested in people?

2 of 119 about aging

Yes: 4 trials and 44 observational studies in people have been published, and 119 trials are registered.

Approved

All 12

Repurposing

40 of 60

Every condition in trials

  • Pick Disease of the Brain

    Phase 4Results posted3 trials

  • Amyloid plaque

    Phase 4Results posted2 trials

  • Cognition disorder

    Phase 4Completed1 trial

  • Acute bipolar depression

    Phase 3Results posted1 trial

  • Autistic disorder

    Phase 3Completed1 trial

  • Attempted Suicide

    Phase 2/3Completed2 trials

All 10

Stopped

  • NCT02909504TerminatedBipolar disorder

    Lack of funding

  • NCT06008249TerminatedAmyotrophic lateral sclerosis

    The planned interim analysis showed no survival benefit of taking the drug when compared with placebo.

  • NCT05126238TerminatedStroke

    Decision of the local ethics committee

  • NCT01928446TerminatedAttempted Suicide

    terminated early due to non-safety related DMC recommendations

  • NCT01105702TerminatedBrain tumor

    Due to slow accrual

  • NCT00997672TerminatedMultiple system atrophy

    Data Monitoring Committee decision on 22nd August 2011 for safety issues

All 8

Who is developing lithium?

3 companies: Alzamend Neuro, Karuna Therapeutics, Inc., a Bristol Myers Squibb company and Merck Sharp & Dohme.

Companies
  • Alzamend NeuroPhase 1/2bipolar i disorder, pharmacokinetic
  • Karuna Therapeutics, Inc., a Bristol Myers Squibb companyPhase 1
  • Merck Sharp & DohmePhase 1

Trial sponsors

Funding

5 grants since 2018

National Institute on Aging$5.4MJapan Society for the Promotion of Science¥4.4MGouvernement du Canada | Canadian Institutes of Health ResearchCA$17.5K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Studies report lithium extends fly lifespan; a mouse study reports improved healthspan without a clear lifespan effect within tolerable doses. A human cohort and reviews link lithium with lower dementia risk, an association reported by independent groups. One registered trial concerns aging; 61 trials across uses lack posted results over a year after ending, and three of 26 papers declare company ties.

  2. Summary rewritten as its findings changed.

    As it read before

    Reviews describe lithium decreasing cellular senescence under stress in experimental studies, alongside human associations with telomere length in bipolar disorder and a reduced risk of dementia and Alzheimer's disease.

  3. Summary written from the findings.

Latest

Dec 2025: 3Jan 2026: 14Feb 2026: 6Mar 2026: 6Apr 2026: 2May 2026: 2Jun 2026: 9Jul 2026: 4Aug 2026: 6Sep 2026: 7Oct 2026: 6Nov 2026: 469 papers in 12 months
Frontiers in Neurology

Starting lithium linked to lower death and dementia risks

Estimated five-year risks were 6.61% versus 10.65% for death and 3.51% versus 4.85% for dementia, comparing lithium with valproate.Estimated five-year risks were 6.61% versus 10.65% for death and 3.51% versus 4.85% for dementia, comparing lithium with valproate.

Cohort study of 22,098 peopleLithium

See all 167 papers on lithium